Efficacy and safety of micafungin in preventing invasive fungal infection in patients with hematological malignancies: a Meta-analysis
KANG Ye, ZHANG Wentao, YAN Lan
2022, 17(1):
12-16.
Asbtract
(
0 )
PDF (1484KB)
(
10
)
References |
Related Articles |
Metrics
Objective To systematically evaluate the effectiveness and safety of micafungin in preventing invasive fungal infections (IFIs) in patients with hematological malignancies, and to provide evidence-based reference for clinical treatment. Methods Computer searching of PubMed, Embase, Cochrane Library, China Knowledge Network (CNKI), Wanfang data from the establishment of the database to January 2021,randomized controlled trials (RCTs) of micafungin (experimental group) compared with conventional antifungal drugs (amphotericin B and triazole antifungal drugs, control group) were collected.After data extraction and quality evaluation with Cochrane system reviewer's manual 5.0.2, Meta analysis was performed on breakthrough IFIs, fungal infection mortality, all-cause mortality and the incidence of drug withdrawal due to adverse reactions with Rev man 5.3 statistical software. Results Nine RCTs involving 2479 patients were included. Meta analysis showed that the incidence of breakthrough IFIs [OR=0.74, 95% CI (0.50, 1.07), P=0.11], mortality of fungal infection [OR=0.73, 95% CI(0.46, 1.17), P=0.19] and all-cause mortality [OR=0.94, 95% CI(0.69, 1.28), P=0.7] in the experimental group were not significantly different from those in the control group; The incidence of drug withdrawal due to adverse reactions [OR=0.46, 95% CI(0.32, 0.66), P<0.0001] was significantly lower than that in the control group, the difference was statistically significant. Conclusion The effect of micafungin in preventing IFIs in patients with hematological malignancies is equivalent to that of amphotericin B and triazole antifungal drugs, and the safety is higher.